NCT05214599撤回2 期
A Phase I/II, Multicenter, Double-blind, Parallel, Randomized Trial to Assess Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults Subjects of Both Genders With Eosinophilic Esophagitis (EoE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Improvement in dysphagia symptoms consistent with the disease
研究概览
简要总结
A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic esophagitis (EoE)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects able to read, understand and sign the Informed Consent Form (ICF) approved by Ethical Committee;
- •Male and female subjects aged between 18 and 75 years old;
- •Body weight between 60-100 kg;
- •Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2;
- •Non-childbearing potential female subjects. Childbearing potential is defined as: post-menopausal women (defined as 12 months of amenorrhea or more), hysterectomized women, oophorectomized (bilateral) women and/or those who underwent tubal ligation;
- •Female participants of childbearing potential who test negative for the pregnancy test on the day of administration of the first dose of the drug (Visit 1), as well as throughout the clinical trial;
- •Female participants who practice adequate contraception or who abstain from all activities that could result in pregnancy for at least 28 days before administering the first dose of the drug (Visit 1);
- •Female participants who agree to continue adequate contraception for 1 month after administration of the last dose of the investigational drug;
- •Participants diagnosed with EoE, verified from a combination of symptoms compatible with EoE and histological finding greater than 15 eosinophils per high-power field in at least one esophageal mucosal biopsy;
- •Participants unresponsive to stable dose of proton-pump inhibitor (PPI).
排除标准
- •Subjects with a malignancy history within the last 5 years, except from successfully treated basal cell carcinoma;
- •History of esophageal stenosis requiring dilation and/or stenosis at endoscopy not allowing to pass the endoscope;
- •Subjects with a eosinophilic gastroenteritis diagnosis (presence of eosinophilic infiltrate in gastric antrum and duodenum);
- •Subjects with a reflux esophagitis history;
- •Subject with a previous serious asthma diagnosis;
- •Subjects with a gastroesophageal tract disease that, at the investigator's discretion, is deemed as an obstacle to take part in the trial;
- •People with chronic diseases on regular drugs that, in the investigator's opinion, may interfere with the trial;
- •Medical conditions such as serious heart or lung diseases preventing the safe performance of endoscopy;
- •Subjects with conditions known to be related to esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia and hypereosinophilic syndrome;
- •Subjects who have been on oral, intranasal or systemic corticosteroid at least 15 days prior to trial start;
- •Smoker of having quit smoking less than 6 months ago;
- •Have a history of excessive alcohol intake for at least 6 months prior to trial start (intake of 5 or more alcoholic beverages in one day or 15 or more alcoholic beverages per week);
- •Subjects having 5 or more cups of tea or coffee per day and who cannot abstain from them for the trial period;
- •Be on CYP3A4 inhibitors, such as ketoconazole and grapefruit juice;
- •Electrocardiogram (ECG) findings that, in the investigator's opinion, may jeopardize participation in the trial;
- •History or presence of gastrointestinal or liver disease or other condition interfering with drug absorption, distribution, excretion or metabolism;
- •Subjects with hypersensitivity or contraindication of using any formulation components;
- •Subjects who have been part of trial protocols in the last 12 (twelve) months (CNS Resolution 251, dated August 7, 1997, item III, sub-item J);
- •Have donated blood (> 500 mL) or undergone major surgery within the 3 months prior to the ICF signature date;
- •Have been vaccinated for the 30 days prior to admission;
- •Clinical evidence of infectious process potentially contributing for dysphagia (candidiasis, cytomegalovirus (CMV), herpes);
- •Other dysphagia cause identified at endoscopy (peptic stenosis, web, ring, achalasia, esophageal neoplasm);
- •Breastfeeding subjects, who plan to become pregnant or with a positive pregnancy test during the trial;
- •Any medical condition or laboratory change that, in the investigator's opinion, may jeopardize participation in the trial.
研究组 & 干预措施
Group 1
Experimental
Low dose
干预措施: Budesonide Gel (Drug)
Group 2
Experimental
Middle dose
干预措施: Budesonide Gel (Drug)
Group 3
Experimental
High dose
干预措施: Budesonide Gel (Drug)
结局指标
主要结局
Improvement in dysphagia symptoms consistent with the disease
时间窗: 8 weeks of treatment
EAT (Eating Assessment Tool) -10 questionnaire
Determination of Pharmacokinetic Profiles
时间窗: First 24 hours after a single drug dose administration
Oral clearance (CL/F)
Proportion of subjects reaching a histological response
时间窗: 8 weeks of treatment
≤ 6 eosinophils per high power field
次要结局
- Assessment of non-serious and serious adverse events rate(Through 8 weeks)
- Quality of life assessment of subjects(Through 8 weeks)
研究者
相似试验
进行中（未招募）
1 期
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersBreast CancerNCT05738993Biocad100
已完成
2 期
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)Sjögren-Larsson SyndromeNCT02402309Aldeyra Therapeutics, Inc.12
进行中（未招募）
2 期
Emodepside Phase II Trial for Treatment of OnchocerciasisOnchocerciasisNCT05180461Drugs for Neglected Diseases578
已完成
1 期
A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic DermatitisAtopic DermatitisNCT03431610Novan, Inc.48
尚未招募
1 期
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.TEDNCT06769984Sinocelltech Ltd.100